Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma

Bibliography

• Cancer Research UK website. Detailed information regarding UK cancer survival statistics for individual tumour types
   Google Scholar
• Steinherz LJ, Steinherz PG, Tan CT, Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266(12):1672-7
   PubMed Web of Science ®Google Scholar
• Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339(13):900-5
   PubMed Web of Science ®Google Scholar
• Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 2004;130(1):1-7
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97(11):2869-79
   PubMed Web of Science ®Google Scholar
• van Dalen EC, van der Pal HJ, Bakker PJ, Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review. Eur J Cancer 2004;40(5):643-52
   PubMed Web of Science ®Google Scholar
• Rodriguez-Monge EJ, Cabanillas F. Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience. Hematol Oncol Clin North Am 1997;11(5):937-47
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Leppa S, Kvaloy S, Holte H. ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma–the Nordic Lymphoma Group experience. Eur J Haematol 2004;73(3):179-82
   PubMed Web of Science ®Google Scholar
• Velasquez WS, Cabanillas F, Salvador P, Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988;71(1):117-22
   PubMed Web of Science ®Google Scholar
• Reiser M, Schnell R, Straub G, DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma. Leuk Lymphoma 1998;31(3-4):359-66
   PubMed Web of Science ®Google Scholar
• Zaja F, Tomadini V, Zaccaria A, CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2006;47(10):2174-80
   PubMed Web of Science ®Google Scholar
• Macpherson N, Belch A, Taylor M, Liposomal encapsulated doxorubicin (Caelyx) in the treatment of relapsed aggressive non-Hodgkin's lymphoma: a phase II study. Leuk Lymphoma 2006;47(7):1327-32
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28(27):4184-90
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Lossos IS, Tuscano JM, Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26(30):4952-7
   PubMed Web of Science ®Google Scholar
• Witzig TE, Reeder CB, LaPlant BR, A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011;25(2):341-7
   PubMed Web of Science ®Google Scholar
• Guidetti A, Carlo-Stella C, Devizzi L, Preliminary results of a phase II trial with the multikinase inhibitor sorafenib in heavily pretreated patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). Blood 2009;114: abstract 1658
   Web of Science ®Google Scholar
• Stopeck AT, Unger JM, Rimsza LM, A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: southwest oncology group study S0108. Leuk Lymphoma 2009;50(5):728-35
   PubMed Web of Science ®Google Scholar
• Goy A, Younes A, McLaughlin P, Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23(4):667-75
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Sharman J, Sweetenham J, Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115(13):2578-85
   PubMed Web of Science ®Google Scholar
• Wilson W, O'Connor C, Czuczman M, Phase 1 study of ABT-263, a Bcl-2 family inhibitor, in relapsed or refractory lymphoid malignancies. Blood 2008;112:abstract 2108
   Google Scholar
• Pro B, Leber B, Smith M, Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol 2008;143(3):355-60
   PubMed Web of Science ®Google Scholar
• Denny WA, Wakelin LP. Kinetics of the binding of mitoxantrone, ametantrone and analogues to DNA: relationship with binding mode and anti-tumour activity. Anticancer Drug Des 1990;5(2):189-200
   PubMedGoogle Scholar
• Mukherji D, Pettengell R. Pixantrone maleate for non-Hodgkin's lymphoma. Drugs Today (Barc) 2009;45(11):797-805
   PubMed Web of Science ®Google Scholar
• Hazlehurst LA, Krapcho AP, Hacker MP. Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells. Biochem Pharmacol 1995;50(7):1087-94
   PubMed Web of Science ®Google Scholar
• Evison BJ, Mansour OC, Menta E, Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent. Nucleic Acids Res 2007;35(11):3581-9
   PubMed Web of Science ®Google Scholar
• Evison BJ, Chiu F, Pezzoni G, Formaldehyde-activated Pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets. Mol Pharmacol 2008;74(1):184-94
   PubMed Web of Science ®Google Scholar
• Evison BJ, Bilardi RA, Chiu FC, CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity. Nucleic Acids Res 2009;37(19):6355-70
   PubMed Web of Science ®Google Scholar
• Mordente A, Meucci E, Silvestrini A, New developments in anthracycline-induced cardiotoxicity. Curr Med Chem 2009;16(13):1656-72
   PubMed Web of Science ®Google Scholar
• Hacker M, McKennon M, Singer J. Lack of iron binding by pixantrone is associated with reduced production of reactive oxygen species and myocyte cytotoxicity in vitro. Blood 2009;114:abstract 4806
   Google Scholar
• El-Helw LM, Hancock BW. Pixantrone: a promising drug in the treatment of non-Hodgkin lymphomas. Future Oncol 2009;5(4):445-53
   PubMed Web of Science ®Google Scholar
• Beggiolin G, Crippa L, Menta E, Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori 2001;87(6):407-16
   PubMed Web of Science ®Google Scholar
• Cavalletti E, Crippa L, Mainardi P, Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Invest New Drugs 2007;25(3):187-95
   PubMed Web of Science ®Google Scholar
• Krapcho AP, Petry ME, Getahun Z, 6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations. J Med Chem 1994;37(6):828-37
   PubMed Web of Science ®Google Scholar
• Faivre S, Raymond E, Boige V, A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Clin Cancer Res 2001;7(1):43-50
   PubMed Web of Science ®Google Scholar
• Lim ST, Fayad L, Tulpule A, A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2007;48(2):374-80
   PubMed Web of Science ®Google Scholar
• Dawson LK, Jodrell DI, Bowman A, A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. Eur J Cancer 2000;36(18):2353-9
   PubMed Web of Science ®Google Scholar
• Borchmann P, Schnell R, Knippertz R, Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann Oncol 2001;12(5):661-7
   PubMed Web of Science ®Google Scholar
• Borchmann P, Morschhauser F, Parry A, Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. Haematologica 2003;88(8):888-94
   PubMed Web of Science ®Google Scholar
• Borchmann P, Herbrecht R, Wilhelm M, Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma. Leuk Lymphoma 2011;52(4):620-8
   PubMed Web of Science ®Google Scholar
• Srokowski TP, Liebmann JE, Modiano MR, Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: Phase 1 Study With a Dose-Expansion Cohort. Cancer 2011 DOI:10.1002/cncr.26121
   Web of Science ®Google Scholar
• Pettengell R, Zinzani P, Narayanan G, Phase 3 trial of pixantrone dimaleate compared with other agents as third-line, single-agent treatment of relapsed aggressive non-Hodgkin lymphoma (EXTEND): End of Study Results. Blood 2010;116:abstract 2833
   Google Scholar
• Herbrecht R, Couban S, Weissinger F, CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) compared to CPOP-R (cyclophosphamide, pixantrone, vincristine, prednisone, rituximab) in first-line therapy of diffuse large B-cell lymphoma (DLBCL); an interim analysis. Blood 2007;110:abstract 3445
   Google Scholar
• Santoro A, Voglova J, Gabrail N, Comparative trail of BBR 2778 (pixantrone) + rituximab vs single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin's lymphoma (NHL). J Clin Oncol 2006;24:abstract 7578
   Google Scholar
• Mukherji D, Pettengell R. Pixantrone for the treatment of aggressive non-Hodgkin lymphoma. Expert Opin Pharmacother 2010;11(11):1915-23
   PubMed Web of Science ®Google Scholar